Hepatitis B study in Guinea-Bissau will not move forward

A Hepatitis B study in Guinea-Bissau that was to be funded by the US Centers for Disease Control and Prevention (CDC) will not move forward.
The study was to be funded with $1.6m from the CDC, along with $1.6m from private partners including the Bluebell Foundation and the Pershing Square Foundation, which is backed by Bill Ackman. The government of Guinea-Bissau now has control over the researchers' vaccines, which were apprehended when authorities searched the offices of the Bandim Health Project on Monday.
The Danish researchers, led by Schaltz-Buchholzer, Christine Stabell Benn and Peter Aaby, hypothesised that giving live vaccines, like the Bacillus Calmette-Guérin (BCG), may have an overall mortality benefit, but giving another vaccine like hepatitis B alongside it could dampen that effect. Schaltz-Buchholzer also cast doubt on the effectiveness and safety of the hepatitis B vaccine at birth, noting that the study was cancelled because it challenges prevailing medical assumptions.
Vaccines expert Paul Offit, from the Children’s Hospital of Philadelphia, criticised the proposed study as unethical. He said the solution is to take the money and vaccinate as many kids as possible, noting that Guinea-Bissau currently plans to offer the universal birth dose in 2028.
Henrik Støvring, a Danish researcher, said that those who declined participation in the study would not have received the vaccines, making true informed consent impossible. He noted that if mothers decide to participate in the trial, they have a 50% chance of getting the vaccine for their children, but if they stay out, they have a 0% chance.
The Minister of Health in Guinea-Bissau, Quinhin Nantote, previously denied that the project would move forward. He added that there is a clear benefit to giving the vaccine to babies as soon as possible because of high rates of hepatitis B in the country and the possibility of lifelong illness and death from infection.
Key facts
- The Hepatitis B study in Guinea-Bissau will not move forward because researchers were not given necessary governmental approval.
- The study was to be funded by $1.6m from the CDC and $1.6m from private partners.
- The government of Guinea-Bissau has control over vaccines apprehended during a search of the Bandim Health Project offices on Monday.
Three perspectives
Neutral
The proposed Hepatitis B study in Guinea-Bissau has been halted following a lack of governmental approval and criticism regarding its ethics.
Positive
The WHO recommends that all infants receive a first dose of the hepatitis B vaccine as soon as possible after birth to ensure timely, evidence-based protection.
Negative
Experts say that because those who declined participation in the study would not have received the vaccines, true informed consent was impossible.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.